Literature DB >> 28593485

Diffuse large B-cell lymphoma presenting as bilateral renal infiltration leading to acute kidney injury.

Tomoe Okubo1, Shuma Hirashio1,2, Minako Shimizu1, Yoshiaki Kuroda3,4, Shigehiro Doi1, Takao Masaki5.   

Abstract

Acute kidney injury (AKI) because of bilateral renal infiltration is an uncommon presentation of diffuse large B-cell lymphoma (DLBCL). A 52-year-old man presented to our institution with AKI and complaints of fatigue. Ultrasonography revealed a large, 15 cm granulomatous mass arising from the bilateral kidneys. The mass was biopsied laparoscopically, and histopathological analysis revealed evidence of DLBCL. The patient subsequently underwent R-CHOP therapy (rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone). Chemotherapy resulted in a rapid decrease in mass size and improvement in kidney function. However, after five courses of R-CHOP, relapse was observed in the central nervous system, and the patient died 220 days after the initial onset of AKI. Post-mortem analysis of renal tissue confirmed the initial diagnosis of DLBCL-associated renal infiltration. To our knowledge, this is the first report of DLBCL presenting as bilateral renal infiltration and AKI.

Entities:  

Keywords:  Acute kidney injury; Central nervous system relapse; Diffuse large B-cell lymphoma; Kidney infiltration

Year:  2017        PMID: 28593485      PMCID: PMC5694399          DOI: 10.1007/s13730-017-0261-6

Source DB:  PubMed          Journal:  CEN Case Rep        ISSN: 2192-4449


  13 in total

1.  Lymphomatous infiltration of the kidney associated with glomerulopathy presenting as acute renal failure.

Authors:  L Feldman; A Basok; L Kachko; D Tovbin
Journal:  Isr Med Assoc J       Date:  2001-07       Impact factor: 0.892

Review 2.  Cell adhesion receptors in lymphoma dissemination.

Authors:  P Drillenburg; S T Pals
Journal:  Blood       Date:  2000-03-15       Impact factor: 22.113

3.  Renal lesions associated with malignant lymphomas.

Authors:  J RICHMOND; R S SHERMAN; H D DIAMOND; L F CRAVER
Journal:  Am J Med       Date:  1962-02       Impact factor: 4.965

4.  Diffuse large B-cell lymphoma with involvement of the kidney: outcome and risk of central nervous system relapse.

Authors:  Diego Villa; Joseph M Connors; Laurie H Sehn; Randy D Gascoyne; Kerry J Savage
Journal:  Haematologica       Date:  2011-04-12       Impact factor: 9.941

5.  Renal involvement in patients with non-Hodgkin's lymphoma: clinical and pathological features in 23 cases.

Authors:  M A Richards; I Mootoosamy; R H Reznek; J A Webb; T A Lister
Journal:  Hematol Oncol       Date:  1990 Mar-Apr       Impact factor: 5.271

6.  Distinct gene expression profiles: nodal versus extranodal diffuse large B-cell lymphoma.

Authors:  Zeenath Jehan; Abdul K Siraj; Jehad Abubaker; Christian Ruiz; Ronald Simon; Mehar Sultana; Shahab Uddin; Prashant Bavi; Azhar Hussain; Shirin Razack; Adnan Ezzat; Fouad Al-Dayel; Guido Sauter; Khawla S Al-Kuraya
Journal:  Oncology       Date:  2008-09-12       Impact factor: 2.935

7.  Primary renal lymphoma. Does it exist?

Authors:  L B Kandel; D L McCullough; L H Harrison; R D Woodruff; E T Ahl; H A Munitz
Journal:  Cancer       Date:  1987-08-01       Impact factor: 6.860

8.  Primary renal lymphoma presenting as acute renal failure.

Authors:  L D Truong; S Soroka; A V Sheth; M Kessler; C Mattioli; W Suki
Journal:  Am J Kidney Dis       Date:  1987-06       Impact factor: 8.860

Review 9.  Acute renal failure due to bilateral lymphomatous infiltrates. Primary extranodal non-Hodgkin's lymphoma (p-EN-NHL) of the kidneys: does it really exist?

Authors:  M L Malbrain; G L Lambrecht; R Daelemans; R L Lins; P Hermans; P Zachée
Journal:  Clin Nephrol       Date:  1994-09       Impact factor: 0.975

10.  Acute renal failure due to non-Hodgkin lymphoma infiltration of the kidneys detected by ultrasonography and confirmed by positron emission tomography.

Authors:  S Simsek; A L Oen; E F I Comans; J J M v d Hoeven; J Zijlstra
Journal:  Clin Nephrol       Date:  2003-05       Impact factor: 0.975

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.